Application of Cellular Technologies to the Experimental Treatment of Destructive Inflammatory Arthropathies
Main Article Content
Abstract
Introduction. The treatment of destructive inflammatory joint diseases (arthropathies) is one of the issues of current interest in modern medicine. In destructive inflammatory diseases, the regenerative ability of cartilaginous tissue proves to be inadequate for neogenesis of joints. The goal of this study is to determine the efficacy of bone marrow-derived mononuclear cell fraction (MNC) and multipotent mesenchymal stromal cells (MMSC) in the treatment of destructive inflammatory joint diseases.
Materials and methods. The study subjects consisted of 15 male rabbits weighing 3-4 kg with experimental destructive inflammatory knee joint disease. The test animals were divided into 3 groups: reference group without treatment, first test group – introduction of autologous MNC from rabbit bone marrow into the affected joint, and second test group – introduction of cultured MMSC from rabbit bone marrow into the joint.
Results. A morphological examination of the synovial membranes in the reference group on the 40th day of the experiment revealed chronic synovitis with destruction of synoviocytes, thickening and inflammatory infiltration of the underlying connective tissue (subintima). During examination of synovial membranes in the first test group the patches of thickened regenerating inner layer (intima) made up by large proliferating synoviocytes were observed. The layer of loose connective tissue (subintima) contained a large number of small blood vessels and was only slightly infiltrated by inflammatory cells. The morphological examination of synovial membranes in the second test group discovered thickened regenerating intimal layer sitting on hypertrophied subintima with dense vascular network. Elastic collagenous layers of synovial membrane adjoined proliferating elements in cartilage plates.
Conclusion. Both autologous MNC fraction and MMSC from bone marrow proved effectiveness in the treatment of destructive inflammatory joint diseases which stimulate neoangiogenesis. At the same time, it must be noted that the introduction of MMSC diminished destructive changes and accelerated proliferative process.
Article Details
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Revised 7/16/2018. Revision Description: Removed outdated link.